Phase 3
N=27
Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model
Caries
Bottom Line
View on ClinicalTrials.gov: NCT03383783 ↗Enrolled (actual)
27
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Percentage Surface Microhardness Recovery (%SMH) — 13.96; 30.59; 40.74; 48.28 Percent Surface Microhardness Recovery
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- 0 ppm F (placebo, negative control) (Drug); 250 ppm F as NaF (dose-response control) (Drug); 500 ppm F as NaF (dose-response control) (Drug); 1100 ppm F as NaF (positive control) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Domenick Zero
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage Surface Microhardness Recovery (%SMH) |
13.96; 30.59; 40.74; 48.28; 7.42; 16.27 | — |
| SECONDARY Net Acid Resistance (NAR) |
-22.68; 11.43; 18.66; 31.79; -18.60; 1.99 | — |
| SECONDARY Comparative Acid Resistance (CAR) |
36.42; 19.20; 22.16; 16.27; 25.82; 14.31 | — |
| SECONDARY Enamel Fluoride Uptake (EFU) |
0.96; 2.25; 2.69; 2.98; 0.96; 2.14 | — |
| SECONDARY Transverse Microradiography (TMR) - Integrated Mineral Loss - ∆Z |
1240; 902; 664; 684; 1526; 912 | — |
| SECONDARY Transverse Microradiography (TMR) - Lesion Depth - L |
52.01; 41.74; 34.85; 27.31; 60.73; 42.12 | — |
| SECONDARY Transverse Microradiography (TMR) - Maximum Mineral Density at the Surface-zone |
62.17; 62.54; 67.13; 65.93; 61.22; 62.99 | — |
Summary
The purpose of this study is to evaluate the fluoride dose response of different dentifrice fluoride concentrations - 0, 250, 500 and 1100 ppm fluoride of our existing in situ model involving the use of human enamel specimens placed in the buccal flange area of the subjects partial denture with the modified model involving placement of bovine enamel specimens in a denture tooth location.
Eligibility Criteria
Inclusion Criteria
- provide voluntary, written informed consent;
- be between 18 and 85 years old;
- understand and be willing, able and likely to comply with all study procedures and restrictions;
- be wearing a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two enamel specimens (required dimensions 12 × 7 mm) and room on the same side to accommodate two 4 mm round specimens in the buccal surface of two posterior denture teeth;
- be willing and capable of wearing their removable partial denture 24 hours a day for four (4), two-week treatment periods;
- be willing to allow study personnel to drill specimen sites (as described #4) in their mandibular partial denture;
- be in good medical and dental health with no active caries or periodontal disease; NOTE; subjects presenting at screening with caries may continue in the study if their carious lesions are restored prior to beginning treatment 1.
- have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min).
Exclusion Criteria
- currently be pregnant, intending to become pregnant during the study period or breast feeding;
- currently have any medical condition that could be expected to interfere with the subject's safety during the study period;
- currently be taking antibiotics or have taken antibiotics in the two weeks prior to the beginning treatment 1;
- have participated in another clinical study or receipt of an investigational drug within 30 days of beginning treatment 1; or
- be taking fluoride supplements, required to use a fluoride mouthrinse or have received a professional fluoride treatment in the two weeks preceding specimen placement;
- be taking or have ever taken bisphosphonate drugs (e.g., Fosamax, Actonel and Boniva) for the treatment of osteoporosis;
Data sourced from ClinicalTrials.gov (NCT03383783). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.